SCHEMBL3877151

SCHEMBL3877151

CC(C)(C)C1NC(=O)NC1=O

nearest known ligand 0.48

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
RGS12 O14924 1/20 0.33
BACE1 P56817 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
LMNA P02545 1/20 0.32
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10914312 0.81 TSHR (0.44) TSHRRGS12BACE1TDP1LMNA
SCHEMBL20435093 0.81 TSHR (0.44) TSHRRGS12BACE1TDP1LMNA
SCHEMBL3282408 0.81 TSHR (0.44) TSHRRGS12BACE1TDP1LMNA
SCHEMBL941641 0.78 TSHR (0.41) TSHRLMNAALDH1A1MAPT
SCHEMBL7760124 0.76 TSHR (0.40) TSHRRGS12LMNA
SCHEMBL6413977 0.72 TSHR (0.40) TSHRLMNAALDH1A1MAPT
SCHEMBL112153 0.72 TSHR (0.40) TSHRRGS12LMNAALDH1A1MAPT
SCHEMBL17676993 0.70 CREBBP (0.58) TSHRLMNAALDH1A1MAPT
SCHEMBL18799320 0.70 TSHR (0.48) TSHRRGS12BACE1TDP1ALDH1A1
SCHEMBL9963916 0.69 TSHR (0.34) TSHRTDP1LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0759475-B1 Method for the production of (R)-ter-leucine DEGUSSA (DE) 1999-08-25 EP claimed
JP-9103297-A None JP disclosed
JP-7222593-A None JP disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 US disclosed
US-20230257367-A1 NOVEL THYROID HORMONE BETA RECEPTOR AGONIST CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) 2023-08-17 US disclosed
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-01-26 US disclosed
CN-113861056-A Synthetic method of hydrophilic micromolecule amino acid 上海弘渼生物科技有限公司 2021-12-31 CN disclosed
US-20200354384-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2020-11-12 US disclosed
CN-111676256-A Biological preparation method of L-tert-leucine 南通大学 2020-09-18 CN disclosed
EP-0745678-A2 Novel microorganism, its use and process for the preparation of L-alpha-aminoacids Degussa Aktiengesellschaft (DE) 1996-12-04 EP disclosed
US-5516660-A FROM CORRESPONDING HYDANTOINS OR CARBAMOYL AMINO ACIDS;ENZYMATIC CONVERSION IN PRESENCE OF ARTHOBACTER DEGUSSA AKTIENGESELLSCHAFT (DE) 1996-05-14 US disclosed
JP-H07222593-A PRODUCTION OF N-CARBAMYL-L-TERT-LEUCINE AJINOMOTO CO INC 1995-08-22 JP disclosed
EP-0625571-A2 Microorganisms, their use and method of production of L-alpha-amino acids Degussa Aktiengesellschaft (DE) 1994-11-23 EP disclosed
EP-0160618-B1 HYDANTOIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1991-08-14 EP disclosed
US-4332953-A FOR PREPARING URETHANE FOAMS AND ELASTOMERS BASF WYANDOTTE CORPORATION (US) 1982-06-01 US disclosed
US-4331809-A INTERMEDIATES FOR PREPARING POLYURETHANE FOAMS AND ELASTOMERS BASF WYANDOTTE CORPORATION (US) 1982-05-25 US disclosed
US-4331810-A Carbamylbiuret-modified polyisocyanates BASF WYANDOTTE CORPORATION (US) 1982-05-25 US disclosed
US-4330636-A Carbamylbiuret-modified polyisocyanates BASF WYANDOTTE CORPORATION (US) 1982-05-18 US disclosed
US-4271087-A WHICH CAN ALSO CONTAIN GUANIDINE LINKAGES AND THIOUREA LINKAGES BASF WYANDOTTE CORPORATION (US) 1981-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354384-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C TSHR 3245/4885RGS12 750/4885BACE1 1626/4885
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C TSHR 3245/4885RGS12 750/4885BACE1 1626/4885
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C TSHR 3245/4885RGS12 750/4885BACE1 1626/4885
US-11767334-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C TSHR 3245/4885RGS12 750/4885BACE1 1626/4885
US-20230257367-A1 NOVEL THYROID HORMONE BETA RECEPTOR AGONIST THRB, THRA, TSHR TSHR 3/4885RGS12 1278/4885BACE1 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.